Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04286607 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

333

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG: Topical roflumilast

Sponsor

Arcutis Biotherapeutics, Inc.